News

NanoViricides, a nano-biopharmaceutical company, has reported that it is developing FluCide, its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown

Ocera Therapeutics, a biopharmaceutical company, has reported positive data from its Phase II study of AST-120 for the treatment of patients with low-grade hepatic encephalopathy. The study showed

Isotechnika, a biopharmaceutical company, has reported that its Essence Phase III trial of voclosporin in moderate to severe psoriasis patients successfully met the primary endpoint of superiority to

The company reported net revenues of $5.38 billion for the first quarter of 2008, a decrease of 6%, compared to $5.71 billion for the first quarter of 2008.

According to Novartis, these data reinforce previous results from the Transforms study announced in December 2008 showing that the relapse rate at one year was 52% lower in

In the Phase IIa trial of 129 migraine patients, significantly more patients taking ADX10059 than those taking placebo (16.7% versus 4.7%, respectively p = 0.039) were pain-free two

According to Iridex, the IQ 577 is a high-power, true yellow laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular

The company has already expressed virus like particles (VLP) of the following pandemic strains in plants: Singapore (H2N2), Anhui (H5N1), Vietnam (H5N1), Hong Kong (H6N1 and H9N2), Equine/Prague

Definitive LE is a prospective, multi-center, single-arm study to evaluate the intermediate and long-term effectiveness of stand-alone SilverHawk plaque excision therapy for endovascular treatment of lower extremity peripheral